fda compounding glp-1 enforcement news november 2025 Issues 30 Warning Letters to Telehealth Firms Over Misleading Compounded Marketing Did the FDA Ban Compounded

Drug Bank, Sermorelin, Pharmacology

No formal a priori sample size calculation was performed

Analysts Viewpoint regarding GLP-1 Analogues Market GLP-1 analogues market is driven by strong clinical evidence demonstrating benefits to the cardiovascular and metabolic systems, growing healthcare spending, and extended reimbursement plans that further enhance patient access

FDA-watchers say the most likely outcome may be a temporary policy reassuring pharmacies that they wont be targeted for compounding the peptides under review

10.18097/PBMC20196503165 58 SealeL

Mechanism of Action: Ipamorelin binds selectively to GH-releasing receptors in the pituitary gland, promoting a natural increase in GH production